{
  "id": 11405808,
  "title": "Needham initiates LB Pharmaceuticals stock with buy rating",
  "url": "https://urgent.news/2026/10/02/needham-initiates-lb-pharmaceuticals-stock-with-buy-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-02T09:22:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/needham-initiates-lb-pharmaceuticals-stock-with-buy-rating-93CH-4929234"
  },
  "original_language": "en",
  "account": "Needham has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with a positive outlook, assigning the stock a \"buy\" rating. The price target set is $68.00, while the current trading price stands at $37.28, marking a substantial 141% increase over the past year. Despite this robust performance, data from InvestingPro indicates the stock may be slightly overvalued compared to its estimated fair value.\n\nLB Pharmaceuticals' focus is on its lead drug candidate, LB-102, which the company describes as an advanced version of amisulpride, an antipsychotic medication utilized globally outside the United States. LB-102 is touted as being de-risked due to its foundation on robust existing data.\n\nThe firm's optimism is further bolstered by data from the NOVA-1 trial, conducted on schizophrenia patients. This trial demonstrated both the efficacy and safety of LB-102, with side effects notably lower than those observed with other D2 agents. Notably, weight gain, a common concern with similar medications, is anticipated to be minimal and self-limiting, mirroring the experience with amisulpride.\n\nLooking ahead, analysts project significant sales potential for LB-102, estimating revenues of about $2.9 billion by 2035 across its initial three indications. This projection surpasses the consensus estimate of $2.8 billion.\n\nWhile LB Pharmaceuticals boasts a solid financial foundation—exhibiting more cash reserves than debt—the firm does not anticipate profitability in the current fiscal year, as highlighted by InvestingPro Tips. The drug candidate's unique bimodal mechanism of action holds promise for treating multiple conditions, including borderline personality disorder and adjunctive treatment for major depressive disorder.\n\nKey upcoming milestones include FDA approval of a study on negative symptoms, projected for the end of 2026, followed by Phase 3 data in schizophrenia in the first half of 2027 and Phase 2 data in adjunctive treatment for borderline personality disorder in the first quarter of 2028.\n\nIn related news, other analysts have also expressed positive sentiments towards LB Pharmaceuticals. H.C. Wainwright recently raised its price target to $60, maintaining a Buy rating, citing the company's progress with LB-102, which is in advanced clinical trials for psychosis and mood disorders. Similarly, Stifel increased its price target to $53, anticipating further indications for LB-102, including Alzheimer’s and negative symptoms in schizophrenia. Piper Sandler reiterated an Overweight rating with a more ambitious price target of $78, recognizing the company's strategic move with a $150 million private placement for expanded research into additional therapeutic areas.\n\nMoreover, H.C. Wainwright reaffirmed its Buy rating with an updated price target of $45 following the announcement of an accelerated timeline for the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia, with anticipated results in the first half of 2027.\n\nBMO Capital Markets also weighed in, initiating coverage with an Outperform rating and a price target of $46, citing promising early Phase 2 data for LB-102 that could distinguish it from existing treatments for schizophrenia.\n\nCollectively, these insights from multiple analyst firms underscore a prevailing sense of optimism and confidence in LB Pharmaceuticals’ future prospects, driven by the anticipated advancements of its lead drug candidate, LB-102.",
  "summary": null,
  "key_points": [
    "Needham initiates LB Pharmaceuticals (LBRX) with buy rating",
    "Stock price target set at $68.00, up 141% from $37.28",
    "LB-102 drug candidate shows efficacy, minimal side effects"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}